Bryan Valcarcel

Bryan Valcarcel

Auto-generated profile, based on publicly available information

Bryan Valcarcel

Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston, TX

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JTJ. Smith Torres-Roman
J. Smith Torres-Roman
JYJorge Ybaseta-Medina
Jorge Ybaseta-Medina
SLSilvana Loli-Guevara
Silvana Loli-Guevara
JBJanina Bazalar-Palacios
Janina Bazalar-Palacios
BVBryan Valcarcel
Bryan Valcarcel
YHYamilee Hurtado-Roca
Yamilee Hurtado-Roca
Background: Breast cancer is among the leading cause of cancer-related mortality among Latin American and Caribbean (LAC) women, but a comprehensive and updated analysis of mortality trends is lacking. The objective of this study was to determine the breast cancer mortality rates between 1997 and 2017 for LAC countries and predict mortality until 2030. Methods: We retrieved breast cancer deaths across 17 LAC countries from the World Health Organization mortality database. Age-standardized mortality rates per 100,000 women-years were estimated. Mortality trends were evaluated with Joinpoint regression analyses by country and age group (all ages, < 50 years, and ≥ 50 years). By 2030, we predict number of deaths, mortality rates, changes in population structure and size, and the risk of death from breast cancer. Results: Argentina, Uruguay, and Venezuela reported the highest mortality rates throughout the study period. Guatemala, El Salvador, and Nicaragua reported the largest increases (from 2.4 to 2.8% annually), whereas Argentina, Chile, and Uruguay reported downward trends (from − 1.0 to − 1.6% annually). In women < 50y, six countries presented downward trends and five countries showed increasing trends. In women ≥ 50y, three countries had decreased trends and ten showed increased trends. In 2030, increases in mortality are expected in the LAC region, mainly in Guatemala (+ 63.0%), Nicaragua (+ 47.3), El Salvador (+ 46.2%), Ecuador (+ 38.5%) and Venezuela (+ 29.9%). Conclusion: Our findings suggest considerable differences in breast cancer mortality across LAC countries by age group. To achieve the 2030 sustainable developmental goals, LAC countries should implement public health strategies to reduce mortality by breast cancer.

20 February 2023 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
GKGabriel De la Cruz Ku
Gabriel De la Cruz Ku
DCDiego Chambergo-Michilot
Diego Chambergo-Michilot
APArmando Perez
Armando Perez
BVBryan Valcarcel
Bryan Valcarcel
LPLarissa Pamen
Larissa Pamen
JBJudy C. Boughey
Judy C. Boughey

1 September 2020 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
JTJ. Smith Torres-Roman
J. Smith Torres-Roman
IKIlia Cabos Kobiak
Ilia Cabos Kobiak
BVBryan Valcarcel
Bryan Valcarcel
CDCristian Diaz-Velez
Cristian Diaz-Velez
CVCarlo La Vecchia
Carlo La Vecchia

24 August 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GKGabriel De la Cruz Ku
Gabriel De la Cruz Ku
MLMarianne Luyo
Marianne Luyo
ZMZaida Morante
Zaida Morante
DEDaniel Enriquez
Daniel Enriquez
MMMecker G. Möller
Mecker G. Möller
BVBryan Valcarcel
Bryan Valcarcel
Epidemiological studies commonly identify the clinical characteristics and survival outcomes of patients with breast cancer at five years. Our study aims to describe the sociodemographic, clinicopathological characteristics and determine the long-term event-free survival (EFS) and overall survival (OS) of a Peruvian population with triple-negative breast cancer. We reviewed the medical records of new cases treated at a single institution in the period 2000–2014. The survival analysis included patients with stages I-IV. Survival estimates at 10 years were calculated with the Kaplan-Meier method and compared with the Log-rank test. We further used multivariate Cox regression analysis to calculate prognostic factors of recurrence and mortality. Among the 2007 patients included, the median age at diagnosis was 49 years (19–95 years). Most patients presented histologic grade III (68.7%), tumor stage II (34.2%), and III (51.0%) at diagnosis. Local and distant relapse was present in 31.9 and 51.4% of the patients, respectively. The most frequent sites of metastasis were the lungs (14.5%), followed by bone (9.7%), brain (9.6%), and liver (7.9%). The median follow-up was 153 months. At 3, 5, and 10 years, the EFS of the population was 55%, 49%, and 41%, respectively, while the OS was 64%, 56%, and 47%, respectively. Moreover, an N3 lymph node status was the most important prognostic factor for both disease relapse (HR: 2.54, 95% CI: 2.05–3.15) and mortality (HR: 2.51, 95% CI: 2.01–3.14) at ten years. An older age and higher T staging were associated with a worse OS, while patients who received radiotherapy and adjuvant chemotherapy had better survival rates. The sociodemographic features of Peruvian patients with TNBC are similar to those of other populations. However, our population was diagnosed at more advanced clinical stages, and thus, EFS and OS were lower than international reports while prognostic factors were similar to previous studies.

1 March 2023 in JCO Global Oncology
Verified
Journal Article
Open access
BVBryan Valcarcel
Bryan Valcarcel
DEDaniel Enriquez-Vera
Daniel Enriquez-Vera
GKGabriel De la Cruz Ku
Gabriel De la Cruz Ku
DCDiego Chambergo-Michilot
Diego Chambergo-Michilot
HCHafid Calderón-Huaycochea
Hafid Calderón-Huaycochea
LMLuis Malpica
Luis Malpica
PURPOSE: Human T-lymphotropic virus type 1 (HTLV-1) is an endemic virus in Latin America that is directly linked to adult T-cell leukemia/lymphoma (ATL). Previous studies have suggested an oncogenic role of HTLV-1 in non-ATL neoplasms and have found higher mortality in HTLV-1 carriers without ATL. METHODS: In this retrospective cohort study, HTLV-1 carriers were identified through screening at a tertiary cancer center between 2006 and 2019. We compared the overall survival (OS) outcomes of patients with ATL with those with other solid or hematologic malignancies by sex stratification. RESULTS: We identified 1,934 HTLV-1 carriers diagnosed with cancer. The median age at diagnosis was 62 (range 20-114) years, 76% were female, 60% had no or elementary school education, and 50% were born in the Andean highlands. The most common non-ATL neoplasm was cervical cancer (50%) among females and non-ATL non-Hodgkin lymphoma (26%) among males. With a median follow-up of 66 months, the 5-year OS of HTLV-1 carriers with non-ATL neoplasms (26%-47% for females and 22%-34% for males) was inferior to those reported in the general population. As expected, patients with ATL had a worse prognosis (5-year OS: 10% for females and 8% for males). CONCLUSION: HTLV-1 carriers with cancer were middle age and from underprivileged settings, suggesting an undetected transmission among vulnerable populations, especially females. Survival estimates of HTLV-1 carriers with non-ATL neoplasms were lower than the regional outcomes. Future research should ascertain how the biology of HTLV-1 and health care disparities affect the outcomes of HTLV-1 carriers, as well as determine the burden of HTLV-1 infection in the cancer population to recommend screening in the outpatient setting of endemic regions.

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ZMZaida Morante
Zaida Morante
GKGabriel De la Cruz Ku
Gabriel De la Cruz Ku
DEDaniel Enriquez
Daniel Enriquez
ASAntonella Saavedra
Antonella Saavedra
MLMaria Luján
Maria Luján
HGHenry Leonidas Gomez
Henry Leonidas Gomez
E13120Background: Prediction of clinical behavior of triple-negative breast cancer (TNBC) is difficult to achieve. Furthermore, it is characterized by a high rate of recurrences and worse outcomes,...